How patients responded to GAZYVA + chlorambucil chemotherapy vs rituximab + chlorambucil

In a clinical trial, the combination of GAZYVA and chlorambucil was studied against the combination of rituximab and chlorambucil. Rituximab is another antibody therapy, and chlorambucil is a type of chemotherapy. The results highlighted below were from a clinical trial and may not be the same as what you experience.

GAZYVA taken with chlorambucil chemotherapy versus rituximab + chlorambucil allowed some patients in the study to experience a median of 26.7 versus 14.9 months, respectively, without their cancer getting worse.

GAZYVA Patient CLL-11 PFS Image

These results were from a clinical trial and may not be the same as what you experience.

 

Nearly 80% of patients had a partial or complete response to GAZYVA + chlorambucil chemotherapy vs rituximab + chlorambucil. Your doctor may refer to this as remission.

GAZYVA Patient CLL-11 PR and CR Image

These results were from a clinical trial and may not be the same as what you experience.

Remission can be partial or complete. Partial remission means the cancer is greatly improved, but evidence of cancer remains. Complete remission means all evidence of the cancer is gone for a period of time.

 

More than 1 in 4 patients who took GAZYVA + chlorambucil chemotherapy vs rituximab + chlorambucil went into complete remission* for a period of time.

GAZYVA Patient CLL-11 MRD Image

These results were from a clinical trial and may not be the same as what you experience.

This study included 781 patients:
  • Eight out of 10 patients in the study were 65 years or older
  • They were an average age of 73 years
Patients had other medical conditions such as:
  • High blood pressure
  • Diabetes
  • Heart or kidney conditions